Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Inventor: Robert J. Hariri
Current U.S. Classification: 435/366

View patent at USPTO
Search USPTO Assignment Database

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US7468276Jun 22, 2004Dec 23, 2008Anthrogenesis CorporationPlacental stem cells
US7682803Oct 13, 2006Mar 23, 2010Anthrogenesis CorporationImmunomodulation using placental stem cells
US7700090Dec 28, 2006Apr 20, 2010Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US7976836Dec 22, 2008Jul 12, 2011Anthrogenesis CorporationTreatment of stroke using placental stem cells
US7993918Aug 3, 2007Aug 9, 2011Anthrogenesis CorporationTumor suppression using placental stem cells
US8057788Dec 28, 2006Nov 15, 2011Anthrogenesis CorporationPlacental stem cell populations
US8057789Oct 31, 2007Nov 15, 2011Anthrogenesis CorporationPlacental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US8071376Oct 13, 2006Dec 6, 2011Anthrogenesis CorporationProduction of oligodendrocytes from placenta-derived stem cells
US8202703Jul 30, 2010Jun 19, 2012Anthrogenesis CorporationPlacental stem cell populations
US8216566Jan 14, 2010Jul 10, 2012Anthrogenesis CorporationTreatment of multiple sclerosis using placental stem cells

Claims

1-23. (canceled)

24. A method of making a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, and comprise stem cells that are CD34− or OCT-4+.

25. The method of claim 24, wherein said placental stem cells are additionally CD10+, CD29+, CD44+, CD45−, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3+ or SSEA4+, or any combination of the foregoing.

26. The method of claim 24, additionally comprising seeding CD34+ human placental stem cells onto said tissue matrix.

27. The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 2 hours.

28. The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 12 hours.

29. The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 24 hours.

30. The method of claim 24, wherein said decellularized tissue is contacted with serum and fibronectin prior to said seeding.

31. A decellularized or synthetic tissue matrix comprising human placental stem cells that are CD34− or OCT-4+.

32. The tissue matrix of claim 31, wherein said placental stem cells are additionally CD10+, CD29+, CD44+, CD45−, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3+ or SSEA4+, or any combination of the foregoing.

33. The tissue matrix of claim 31 additionally comprising CD34+ stem cells.

34. The tissue matrix of claim 31, wherein said tissue matrix comprises a synthetic tissue matrix.

35. The tissue matrix of claim 34, wherein said synthetic tissue matrix comprises polylactide-co-glycolide, a hydrated collagen lattice, or a collagen cross-linked with glycosaminoglycan.

36. The tissue matrix of claim 33, wherein said tissue matrix comprises a synthetic tissue matrix.

37. The tissue matrix of claim 39, wherein said synthetic tissue matrix comprises polylactide-co-glycolide, a hydrated collagen lattice, or a collagen cross-linked with glycosaminoglycan.

38. The tissue matrix of claim 31, wherein the tissue matrix comprises a decellularized tissue.

39. The tissue matrix of claim 39, wherein said decellularized tissue is non-human.

40. The tissue matrix of claim 39, wherein said tissue matrix comprises exogenous fibronectin, glycosaminoglycan, human serum, fetal bovine serum, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-β), fibrillar collagen, or collagen fragments.

41. The tissue matrix of claim 33, wherein the tissue matrix comprises a decellularized tissue.

42. The tissue matrix of claim 41, wherein said decellularized tissue is non-human.

43. The tissue matrix of claim 41, wherein said tissue matrix comprises exogenous fibronectin, glycosaminoglycan, human serum, fetal bovine serum, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-β), fibrillar collagen, or collagen fragments.

Drawings